A case of valproate induced hyperammonemic encephalopathy
Related Experiment Video
Updated: Jun 1, 2026

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
Published on: November 8, 2018
Surjit Tarafdar1, Mark Slee, Faisal Ameer
1Nephrology, Flinders Medical Centre, Bedford Park, SA 5042, Australia.
Abstract:
A 36-years-old man on phenytoin, levetiracetam, and sodium valproate presented with acute confusion. Routine investigations including serum valproate and phenytoin concentration were normal. His serum ammonia concentration was raised. His valproate was held and 2 days later he recovered with concordant normalisation of serum ammonia concentration. Urea acid cycle disorder was ruled out, and a diagnosis of valproate induced hyperammonemic encephalopathy (VHE) was made. Asymptomatic hyperammonemia occurs in 15-50% of valproate-treated patients, and while the true incidence of VHE is not known, it is a recognized complication of sodium valproate treatment. VHE typically presents acutely with impaired consciousness, lethargy, and vomiting. Valproate concentrations may be in the therapeutic range, and liver function tests are typically "normal." Treatment for VHE consists of ceasing valproate and providing supportive care. Some have advocated carnitine replacement.
Related Concept Videos
Hepatic Encephalopathy
Antiepileptic Drugs: Glutamate Antagonists
Encephalitis l: Introduction
Inborn Errors of Metabolism
Encephalitis ll: Pathophysiology
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...